Industry Sponsored Studies

A multicenter, randomized, double-blind, parallel-group, placebo-controlled, Phase 2 study to assess the efficacy and safety of ATX01 (topical amitriptyline hydrochloride 10% and 15%) in cancer survivors with painful chemotherapy-induced peripheral neuropathy (CIPN). (sponsored by Algo Therapeutix).

The purpose of this trial is to compare the efficacy of twice daily applications of ATX01 (10% & 15%) versus placebo during a 12-week treatment period in treating chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivor patients. Dr. Gewandter is the site PI for this trial, with Dr. Annie Philip and Ms. Jacquie Behr serving as clinician Co-Is. Ms. Valerie Chiodo and Dr. Karim Saab are responsible for enrollment and study conduct.

If you would like to know more about this study, please visit clinicaltrials.gov. If you are interested in enrolling, please complete our interest Survey here.